Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5GWY

Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design

5GWY の概要
エントリーDOI10.2210/pdb5gwy/pdb
関連するBIRD辞書のPRD_IDPRD_002214
分子名称main protease, N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE (3 entities in total)
機能のキーワードhcov-nl63, main protease, inhibitor, complex, drug design, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
由来する生物種Human coronavirus NL63 (HCoV-NL63)
詳細
タンパク質・核酸の鎖数4
化学式量合計67710.74
構造登録者
Wang, F.,Chen, C.,Tan, W.,Yang, K.,Yang, H. (登録日: 2016-09-14, 公開日: 2017-09-20, 最終更新日: 2024-11-20)
主引用文献Wang, F.,Chen, C.,Tan, W.,Yang, K.,Yang, H.
Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design.
Sci Rep, 6:22677-22677, 2016
Cited by
PubMed Abstract: First identified in The Netherlands in 2004, human coronavirus NL63 (HCoV-NL63) was found to cause worldwide infections. Patients infected by HCoV-NL63 are typically young children with upper and lower respiratory tract infection, presenting with symptoms including croup, bronchiolitis, and pneumonia. Unfortunately, there are currently no effective antiviral therapy to contain HCoV-NL63 infection. CoV genomes encode an integral viral component, main protease (M(pro)), which is essential for viral replication through proteolytic processing of RNA replicase machinery. Due to the sequence and structural conservation among all CoVs, M(pro) has been recognized as an attractive molecular target for rational anti-CoV drug design. Here we present the crystal structure of HCoV-NL63 M(pro) in complex with a Michael acceptor inhibitor N3. Structural analysis, consistent with biochemical inhibition results, reveals the molecular mechanism of enzyme inhibition at the highly conservative substrate-recognition pocket. We show such molecular target remains unchanged across 30 clinical isolates of HCoV-NL63 strains. Through comparative study with M(pro)s from other human CoVs (including the deadly SARS-CoV and MERS-CoV) and their related zoonotic CoVs, our structure of HCoV-NL63 M(pro) provides critical insight into rational development of wide spectrum antiviral therapeutics to treat infections caused by human CoVs.
PubMed: 26948040
DOI: 10.1038/srep22677
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.852 Å)
構造検証レポート
Validation report summary of 5gwy
検証レポート(詳細版)ダウンロードをダウンロード

234440

件を2025-04-09に公開中

PDB statisticsPDBj update infoContact PDBjnumon